All results

12 results for phase 2 randomized double blind placebo controlled evaluation safety and efficacy bms

• CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

  This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK),…

  Ages

  40 Years - N/A

  Sexes

  All

• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

  This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing…

  Ages

  18 Years - N/A

  Sexes

  All

• PROTECT Extension Study

  The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in…

  Ages

  9 Years - 19 Years

  Sexes

  All

• Trial of DCA in PDCD

  The objective of this research study is to conduct a pivotal phase 3 trial of treatment with the investigational drug dichloroacetate (DCA) in young children…

  Ages

  6 Months - 17 Years

  Sexes

  All

• GALACTIC-1

  This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and…

  Ages

  40 Years - N/A

  Sexes

  All

• NIH AIM 2 - Low Dose Pioglitazone in NASH

  To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…

  Ages

  21 Years - 75 Years

  Sexes

  All

• Vasomune AV001-004

  A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring…

  Ages

  18 Years - N/A

  Sexes

  All

• GCAptAIN

  This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…

  Ages

  50 Years - N/A

  Sexes

  All

• diSArm

  Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…

  Ages

  18 Years - N/A

  Sexes

  All

• Armata

  Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…

  Ages

  18 Years - N/A

  Sexes

  All